TransMedics Group (TMDX) to Release Earnings on Thursday

TransMedics Group (NASDAQ:TMDX) will likely be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect TransMedics Group to post earnings of $0.22 per share and revenue of $109.49 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

TransMedics Group Trading Up 7.2 %

Shares of TransMedics Group stock opened at $77.12 on Tuesday. The firm has a 50-day simple moving average of $66.63 and a two-hundred day simple moving average of $103.87. The company has a market cap of $2.59 billion, a P/E ratio of 82.04 and a beta of 2.12. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Piper Sandler decreased their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, TD Cowen decreased their price target on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, TransMedics Group presently has an average rating of “Moderate Buy” and an average target price of $122.70.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 7.00% of the stock is owned by insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.